"We are enthusiastic about getting patients started in the OCU200 Phase 1 clinical trial and sharing not only safety but ...

Enrollment in DURAVYU Phase 3 wet AMD clinical trials exceeding expectations with the LUGANO trial one-third enrolled and the LUCIA trial ...

The following is a summary of “Microcystoid macular edema in epiretinal membrane: not a retrograde maculopathy,” published in ...

The phase 3 trial showed biosimilar CT-P42 (Celltrion) is therapeutically equivalent to reference aflibercept in improving ...

WATERTOWN, Mass., Jan. 08, 2025 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a company committed to developing and commercializing innovative therapeutics to improve the lives of ...

Phase 1b clinical data underpins sozinibercept's potential as a novel, first-in-class VEGF-C/D 'trap' to improve visual and anatomic outcomes in DME< ...

An announcement from Opthea Limited ( ($AU:OPT) ) is now available. Opthea Limited announced the publication of its Phase 1b ...

Diabetic macular edema (DME) is a complication of diabetes. Over time, high blood sugar levels can cause damage to the tiny blood vessels in the eyes. Globally, about 5.5% of people with diabetes ...

Age-related macular degeneration (AMD) is the primary cause of vision loss in people over 65, marked by abnormal changes in the macula that lead to diminished vision and distorted perception of ...

SEOUL, South Korea — Korean scientists have developed a revolutionary eye drop treatment for dry age-related macular degeneration (AMD), potentially eliminating the need for regular eye injections ...

Either move can cause conjunctivitis, also known as pink eye. Symptoms of pink eye include redness, itchiness, swelling, a gritty sensation, tearing, blurred vision and discharge that forms a ...

Worldwide, age-related macular degeneration (AMD) is the leading cause of severe vision loss in people aged 50 or older. Neovascular AMD is an advanced form of the condition, also known as “exudative ...